Overview

  • Product nameBzATP triethylammonium salt
  • Description
    Potent, prototypic P2X7 agonist. P2 agonist.
  • Biological descriptionPrototypic P2X7 receptor agonist, showing 5-10 fold greater potency than ATP (pEC50 = 6.5). Also exhibits activity at other P2 receptors (EC50 values are 5 and 63 μM at P2X3 and P2Y11, respectively). Shows high potency at P2X1 receptor (pEC50 = 8.7). Potent activator of cAMP production.
  • Purity> 94%

Properties

    References for BzATP triethylammonium salt (ab120444)

    This product has been referenced in:
    • Jacobson KA  et al. Development of selective agonists and antagonists of P2Y receptors. Purinergic Signal 5:75-89 (2009). Read more (PubMed: 18600475) »
    • Michel AD  et al. Serum constituents can affect 2'-& 3'-O-(4-benzoylbenzoyl)-ATP potency at P2X(7) receptors. Br J Pharmacol 132:1501-8 (2001). Read more (PubMed: 11264244) »
    • Boué-Grabot E  et al. Unique functional properties of a sensory neuronal P2X ATP-gated channel from zebrafish. J Neurochem 75:1600-7 (2000). Read more (PubMed: 10987841) »
    • Conigrave AD  et al. Pharmacological profile of a novel cyclic AMP-linked P2 receptor on undifferentiated HL-60 leukemia cells. Br J Pharmacol 124:1580-5 (1998). Read more (PubMed: 9723974) »
    • Bennett CE Fasciola hepatica: development of caecal epithelium during migration in the mouse. Exp Parasitol 37:426-41 (1975). Read more (PubMed: 1126424) »

    See 1 Publication for this product

    Product Wall

    There are currently no Abreviews or Questions for ab120444.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE, NOT FOR USE IN HUMANS"